Phase I dose escalation and pharmacokinetic study of pluronic polymer-bound doxorubicin (SP1049C) in patients with advanced cancer

SP1049C is a novel anticancer agent containing doxorubicin and two nonionic pluronic block copolymers. In preclinical studies, SP1049C demonstrated increased efficacy compared to doxorubicin. The objectives of this first phase I study were to determine the toxicity profile, dose-limiting toxicity, m...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Danson, S, Ferry, D, Alakhov, V, Margison, J, Kerr, D, Jowle, D, Brampton, M, Halbert, G, Ranson, M
Natura: Artigo
Lingua:Inglês
Pubblicazione: Nature Publishing Group 2004
Soggetti:
Clinical
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC2409484/
https://ncbi.nlm.nih.gov/pubmed/15150584
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/sj.bjc.6601856
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi